Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Дискуссионные вопросы клинической, лабораторной и инструментальной диагностики опухолей яичников у женщин репродуктивного возраста (обзор литературы)
Дискуссионные вопросы клинической, лабораторной и инструментальной диагностики опухолей яичников у женщин репродуктивного возраста (обзор литературы)
Подзолкова Н.М., Осадчев В.Б., Бабков К.В., Сафонова Н.Е. Дискуссионные вопросы клинической, лабораторной и инструментальной диагностики опухолей яичников у женщин репродуктивного возраста (обзор литературы). Гинекология. 2020; 22 (1): 7–13. DOI: 10.26442/20795696.2020.1.200009
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Проблема дифференциальной диагностики доброкачественных и злокачественных новообразований на ранних стадиях продолжает оставаться одной из актуальных тем в практической гинекологии. До настоящего времени не разработаны четкие критерии диагностики и скрининга опухолей яичников. Ранние стадии заболевания протекают бессимптомно, и даже при появлении первых симптомов больные часто не обращаются к врачу либо врач не рекомендует оперативное лечение, предпочитая динамическое наблюдение. Современная диагностика опухолей яичников не может основываться на одном методе исследования, а требует целого комплекса диагностических мероприятий, определяющих тактику ведения пациенток в каждом конкретном случае. Наиболее перспективными для изучения являются методы комплексного использования биомаркеров, в том числе с разработкой математических моделей риска злокачественности опухоли яичника, основанных на инструментальных и лабораторных методиках. Несмотря на успехи, достигнутые в выявлении опухолей яичников, имеется необходимость исследования новых современных методов ранней дооперационной диагностики у пациенток разных возрастных периодов, особенно планирующих реализовать репродуктивную функцию.
Ключевые слова: репродуктивная система, новообразования яичников, риск, биомаркеры, диагностика.
Key words: people, gynecology, ovarian tumors, research, doctors, risk, biomarkers.
Ключевые слова: репродуктивная система, новообразования яичников, риск, биомаркеры, диагностика.
________________________________________________
Key words: people, gynecology, ovarian tumors, research, doctors, risk, biomarkers.
Полный текст
Список литературы
1. Ortiz-Muñoz B, Aznar-Oroval E, García García A et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol 2014; 35 (7): 7249–58. DOI: 10.1007/s13277-014-1945-6
2. Борисова Е.А. Комплексная дифференциальная диагностика опухолей придатков матки. Автореф. дис. … канд. мед. наук. Иркутск, 2018.
[Borisova E.A. Kompleksnaia differentsial'naia diagnostika opukholei pridatkov matki. Avtoref. dis. … kand. med. nauk. Irkutsk, 2018 (in Russian).]
3. Серебренникова К.Г., Кузнецова Е.П. Хирургическое лечение доброкачественных опухолей яичников. Фундаментальные исследования. 2011; 9 (1): 155–8.
[Serebrennikova K.G., Kuznetsova E.P. Khirurgicheskoe lechenie dobrokachestvennykh opukholei iaichnikov. Fundamental'nye issledovaniia. 2011; 9 (1): 155–8 (in Russian).]
4. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
[Kaprin A.D., Starinsky V.V., Petrova G.V. The status of cancer care for the population of Russia in 2017. Moscow: MNIOI im. P.A. Gertsena – filial FGBU "NMITs radiologii' Minzdrava Rossii, 2018 (in Russian).]
5. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359–86. DOI: 10.1002/ijc.29210
6. Zola P, Macchi C, Cibula D et al. Follow-up in Gynecological Malignancies A State of Art. Int J Gyn Cancer 2015; 25 (7): 1151–64. DOI: 10.1097/igc.0000000000000498
7. Committee Opinion No. 716. American College of Obstetricians and Gynecologists. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol 2017; 130: e146–9.
8. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am 2018; 32 (6): 943–64. DOI: 10.1016/j.hoc.2018.07.010
9. Воробьев А.В., Протасова А.Э. Общие вопросы скрининга. Практическая онкология. 2010; 11 (2): 53–9.
[Vorob'ev A.V., Protasova A.E. Obshchie voprosy skrininga. Prakticheskaia onkologiia. 2010; 11 (2): 53–9 (in Russian).]
10. Антошечкина М.А., Савинова Е.Б. Иcпользование биомаркеров для ранней диагностики рака яичников. Кремлевская медицина. Клинический вестник. 2011; 4: 91–3.
[Antoshechkina M.A., Savinova E.B. Icpol'zovanie biomarkerov dlia rannei diagnostiki raka iaichnikov. Kremlevskaia meditsina. Klinicheskii vestnik. 2011; 4: 91–3 (in Russian).]
11. Ефимова О.А. Комплексная лучевая диагностика опухолевых образований яичников на дооперационном этапе. Поволжский онкологический вестн. 2017; 3 (30): 61–4.
[Efimova O.A. Kompleksnaia luchevaia diagnostika opukholevykh obrazovanii iaichnikov na dooperatsionnom etape. Povolzhskii onkologicheskii vestn. 2017; 3 (30): 61–4 (in Russian).]
12. Силина И.А. Рак яичника: аспекты диагностики. Лабораторная диагностика. Восточная Европа. 2015; 3–4 (15–16): 159–68.
[Silina I.A. Rak iaichnika: aspekty diagnostiki. Laboratornaia diagnostika. Vostochnaia Evropa. 2015; 3–4 (15–16): 159–68 (in Russian).]
13. Батырова Л.М. Ранняя диагностика рака яичников. Вестник хирургии Казахстана. 2011; 2: 46–7.
[Batyrova L.M. Ranniaia diagnostika raka iaichnikov. Vestnik khirurgii Kazakhstana. 2011; 2: 46–7 (in Russian).]
14. Мехдиев В.Э. Клиническое значение трехмерной трансвагинальной эхографии в режиме цветного и энергетического Доплера в дифференциальной диагностике опухолей и опухолевидных образований яичников. Автореф. дис. … канд. мед. наук. М., 2011.
[Mekhdiev V.E. Klinicheskoe znachenie trekhmernoi transvaginal'noi ekhografii v rezhime tsvetnogo i energeticheskogo Doplera v differentsial'noi diagnostike opukholei i opukholevidnykh obrazovanii iaichnikov. Avtoref. dis. … kand. med. nauk. M., 2011 (in Russian).]
15. Ionescu CA, Matei A, Navolan D et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses. Medicine (Baltimore) 2018; 97 (31): e11762. DOI: 10.1097/MD.0000000000011762
16. Querleu D, Planchamp F, Chiva L et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 2017; 27 (7): 1534–42. DOI: 10.1097/IGC.0000000000001041
17. Gold P, Freedman S. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439–62. DOI: 10.1084/jem.121.3.439
18. Hammarstrom S, Engvall E, Sundblad G. Carcinoembryonic antigen CEA: purification, structure and antigenicproperties, in Health Control in Detection of Cancer, Skandia International Symposia. Bostrom H, Larsson T, Ljungstedt N, eds. 1976; p. 24–39.
19. Khoo S, MacKay E. Carcinoembryonic antigen (CEA) in ovarian cancer: Factors influencing its incidence and changes which occur in response to cytotoxic drugs. Br J Obstet Gynaecol 1976; 83: 753–9. DOI: 10.1111/j.1471-0528.1976.tb00739.x
20. Bast R, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig 1981; 68: 1331–7. DOI: 10.1172/JCI110380
21. Агаджанян К.В., Устьянцева И.М., Петухова О.В., Яковлева Н.В. Клинико-метаболические изменения в зависимости от степени тяжести эндометриоза: материалы III Международного конгресса по репродуктивной медицине «Проблемы репродукции». М., 2009; c. 163.
[Agadzhanian K.V., Ust'iantseva I.M., Petukhova O.V., Iakovleva N.V. Kliniko-metabolicheskie izmeneniia v zavisimosti ot stepeni tiazhesti endometrioza: materialy III Mezhdunarodnogo kongressa po reproduktivnoi meditsine "Problemy reproduktsii'. M., 2009; c. 163 (in Russian).]
22. Li F, Tie R, Chang K et al. Meta-analysis Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer 2012; 12: 258. DOI: 10.1186/1471-2407-12-258
23. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40–6.
24. Kim YM, Whang DH, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective casecontrol study in a Korean population. Clin Chem Lab Med 2011; 49: 527–34.
25. Galgano MT, Hampton GM, Frierson HFJr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847–53.
26. Capriglione S, Luvero D, Plotti F et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol 2017; 34 (9): 164. DOI: 10.1007/s12032-017-1026-y
27. Chen F, Shen J, Wang J et al. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res 2018; 10: 1313–8. DOI: 10.2147/CMAR.S155693
28. Simmons AR, Clarke CH, Badgwell DB et al. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. Int J Gynecol Cancer 2016; 26 (6): 1070–7. DOI: 10.1097/IGC.0000000000000737
29. Ueland F, DeSimone C, Seamon L et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117: 1289–97. DOI: 10.1097/AOG.0b013e31821b5118
30. Zhang Z, Chan D. The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomark Prev 2010; 19: 2995–9. DOI: 10.1158/1055-9965.EPI-10-0580
31. Meys EM, Kaijser J, Kruitwagen RF et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 2016; 58: 17–29. DOI: 10.1016/j.ejca.2016.01.007
32. Гаспаров А.С., Дубинская Е.Д., Паяниди Ю.Г., Бабичева И.А. Онкогинекологические аспекты кистозных образований яичников. Вестн. РАМН. 2013; 8.
[Gasparov A.S., Dubinskaia E.D., Paianidi Iu.G., Babicheva I.A. Onkoginekologicheskie aspekty kistoznykh obrazovanii iaichnikov. Vestn. RAMN. 2013; 8 (in Russian).]
33. Petricoin EF, Liotta LA. SELDI TOF based serum proteomic pattern diagnostics for early detection of cancer. Cur Opinion in Biotechnology 2004; 15 (1): 24–30. DOI: 10.1016/j.copbio.2004.01.005.46
34. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003; 49 (8): 1272–5. DOI: 10.1016/j.copbio.2004.01.005
35. Егунова М.А., Куценко И.Г. Дифференциальная диагностика доброкачественных и злокачественных новообразований яичников (история вопроса). Журн. акушерства и женских болезней. 2016. DOI: 10.17816/JOWD65668-78
[Egunova M.A., Kutsenko I.G. Differentsial'naia diagnostika dobrokachestvennykh i zlokachestvennykh novoobrazovanii iaichnikov (istoriia voprosa). Zhurn. akusherstva i zhenskikh boleznei. 2016. DOI: 10.17816/JOWD65668-78 (in Russian).]
36. Макаров О.В., Нариманова М.Р., Мошковский С.А., Карпова М.А. Перспектива нового способа своевременной диагностики рака яичников на основе использования комбинации сывороточных белков СА125 и SAA-A1. Акушерство и гинекология. 2015; 3: 48–57.
[Makarov O.V., Narimanova M.R., Moshkovskii S.A., Karpova M.A. Perspektiva novogo sposoba svoevremennoi diagnostiki raka iaichnikov na osnove ispol'zovaniia kombinatsii syvorotochnykh belkov SA125 i SAA-A1. Akusherstvo i ginekologiia. 2015; 3: 48–57 (in Russian).]
37. Герфанова Е.В., Ашрафян Л.А., Антонова И.Б. и др. Скрининг рака яичников: реальность и перспективы. Обзор литературы. Опухоли женской репродуктивной системы. 2015; 11 (1): 69–75.
[Gerfanova E.V., Ashrafian L.A., Antonova I.B. et al. Skrining raka iaichnikov: real'nost' i perspektivy. Obzor literatury. Opukholi zhenskoi reproduktivnoi sistemy. 2015; 11 (1): 69–75 (in Russian).]
38. Suh-Burgmann E, Flanagan T, Osinski T et al. Prospective Validation of a Standardized Ultrasonography-Based Ovarian Cancer Risk Assessment System. Obstet Gynecol 2018; 132 (5): 1101–11. DOI: 10.1097/AOG.0000000000002939
39. Valentin L, Ameye L, Savelli L et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol 2011; 38 (4): 456–65. DOI: 10.1002/uog.9030
40. Sehgal N. Efficacy of Color Doppler Ultrasonography in Differentiation of Ovarian Masses. J Midlife Health 2019; 10 (1): 22–8. DOI: 10.4103/jmh.JMH_23_18
41. Kaijser J, Bourne T, Valentin L et al. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol 2013; 41 (1): 9–20. DOI: 10.1002/uog.12323
42. Garg S, Kaur A, Mohi JK et al. Evaluation of IOTA Simple Ultrasound Rules to Distinguish Benign and Malignant Ovarian Tumours. J Clin Diagn Res 2017; 11 (8): TC06–TC09. DOI: 10.7860/JCDR/2017/26790.10353
43. Moro F, Pasciuto T, Djokovic D et al. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol 2019; 53 (1): 116–23. DOI: 10.1002/uog.19174
44. Wynants L, Timmerman D, Verbakel JY et al. Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis. Clin Cancer Res 2017; 23 (17): 5082–90. DOI: 10.1158/1078-0432.CCR-16-3248
45. Подзолкова Н.М., Львова А.Г., Зубарев А.Р., Осадчев В.Б. Дифференциальная диагностика опухолей и опухолевидных образований яичников: клиническое значение трехмерной эхографии. Вопросы гинекологии, акушерства и перинатологии. 2009; 8 (1): 7–16.
[Podzolkova N.M., L'vova A.G., Zubarev A.R., Osadchev V.B. Differentsial'naia diagnostika opukholei i opukholevidnykh obrazovanii iaichnikov: klinicheskoe znachenie trekhmernoi ekhografii. Voprosy ginekologii, akusherstva i perinatologii. 2009; 8 (1): 7–16 (in Russian).]
46. Братчикова О.В. Новые технологии (3D/4D-УЗИ) в определении характера яичниковых образований. Автореф. дис. … канд. мед. наук. М., 2011.
[Bratchikova O.V. Novye tekhnologii (3D/4D-UZI) v opredelenii kharaktera iaichnikovykh obrazovanii. Avtoref. dis. … kand. med. nauk. M., 2011 (in Russian).]
47. Ашрафян Л.А., Ивашина С.В., Когай Н.В. и др. Возможности соноэластометрии для дифференциальной диагностики доброкачественных и злокачественных опухолей яичников. Опухоли женской репродуктивной системы. 2012; 2.
[Ashrafian L.A., Ivashina S.V., Kogai N.V. et al. Vozmozhnosti sonoelastometrii dlia differentsial'noi diagnostiki dobrokachestvennykh i zlokachestvennykh opukholei iaichnikov. Opukholi zhenskoi reproduktivnoi sistemy. 2012; 2. (in Russian).]
48. Henri M, Florence E, Aurore B et al. Contribution of contrast-enhanced ultrasound with Sonovue to describe the microvascularization of uterine fibroid tumors before and after uterine artery embolization. Eur J Obstet Gynecol Reprod Biol 2014; 181: 104–10. DOI: 10.1016/j.ejogrb.2014.07.030
49. Ma X, Zhao Y, Zhang B et al. Contrast-enhanced ultrasound for differential diagnosis of malignant and benign ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 46 (3): 277–83. DOI: 10.1002/uog.14800
50. Meng W, Ying W, Qichao Z et al. Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer. Saudi Med J 2017; 38 (6): 592–7. DOI: 10.15537/smj.2017.6.19790
51. Liu Z, Yang F, Zhang Y et al. Conventional, Doppler and Contrast-Enhanced Ultrasonography in Differential Diagnosis of Ovarian Masses. Cell Physiol Biochem 2016; 39 (6): 2398–408.
52. Агеев А.С., Чекалова М.А., Патютко Ю.И. Ультразвуковое исследование с контрастным усилением в диагностике метастатического поражения печени. Ультразвуковая и функциональная диагностика. 2016; 2: 9–16.
[Ageev A.S., Chekalova M.A., Patiutko Iu.I. Ul'trazvukovoe issledovanie s kontrastnym usileniem v diagnostike metastaticheskogo porazheniia pecheni. Ul'trazvukovaia i funktsional'naia diagnostika. 2016; 2: 9–16 (in Russian).]
53. Ma X, Zhao Y, Zhang B et al. Contrast-enhanced ultrasound for differential diagnosis of benign and malignant ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 46 (3). DOI: 10.1002/uog.14800
54. Соновью. Научная монография. Динамическое контрастное усиление в режиме реального времени. 2013. http://cp6.megagroup.ru/
d/178726/d/monografiya-sonovyu-2013.pdf
[Sonov'iu. Nauchnaia monografiia. Dinamicheskoe kontrastnoe usilenie v rezhime real'nogo vremeni. 2013. http://cp6.megagroup.ru/
d/178726/d/monografiya-sonovyu-2013.pdf (in Russian).]
55. Давыдов А.И., Кузьмина Т.Е. Контрастно-усиленные ультразвуковые исследования в гинекологии. Вопросы гинекологии, акушерства и перинатологии. 2017; 16 (6): 50–8. DOI: 10.20953/1726-1678-2017-6-50-58
[Davydov A.I., Kuz'mina T.E. Kontrastno-usilennye ul'trazvukovye issledovaniia v ginekologii. Voprosy ginekologii, akusherstva i perinatologii. 2017; 16 (6): 50–8.
DOI: 10.20953/1726-1678-2017-6-50-58 (in Russian).]
56. Sahdev A. CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvis disease for surgical planning. Cancer Imaging 2016.
57. Pietro VF, Giancarlo AS et al. MRI of ovarian masses: classification and differential diagnosis insights imaging. Insights Imaging 2016;
7 (1): 21–41.
58. Forstner R, Thamassin-Naggara I et al. ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update. Eur Radiol 2017; 27 (6): 2248–57.
59. Palmeiro MM et al. MRI classification of the Sonographically Indeterminated Adnexal Lesions. Acta Radiologica Portuguesa 2016; XXVIII (108): 37–47.
60. Ma FH, Qiang JW, Cai SQ et al. MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors. AJR Am J Roentgenol 2015; 204 (6): W724–30. DOI: 10.2214/AJR.14.13391
61. Солопова А.Е., Терновой С.К., Устюжанин Д.В., Макаца-
рия А.Д. Магнитно-резонансная спектроскопия в дифференциальной диагностике опухолей яичника. Методика, диагностические возможности, ограничения. DOI: 10.21569/2222-7415-2017-7-1-84-93
[Solopova A.E., Ternovoi S.K., Ustiuzhanin D.V., Makatsariia A.D. Magnitno-rezonansnaia spektroskopiia v differentsial'noi diagnostike opukholei iaichnika. Metodika, diagnosticheskie vozmozhnosti, ogranicheniia. DOI: 10.21569/2222-7415-2017-7-1-84-93 (in Russian).]
62. Sidhu S, Falzon G, Hart SA et al. Classification of breast tissue using a laboratory system for small-angle x-ray scattering (SAXS). Phys Med Biol 2011; 56: 6779–91. DOI: 10.1088/0031-9155/56/21/002
63. Jensen TH, Bech M, Bunk O et al. Brain tumor imaging using small-angle Х-ray scattering tomography. Phys Med Biol 2011; 56: 1717–26. DOI: 10.1088/0031-9155/56/6/012
2. Borisova E.A. Kompleksnaia differentsial'naia diagnostika opukholei pridatkov matki. Avtoref. dis. … kand. med. nauk. Irkutsk, 2018 (in Russian).
3. Serebrennikova K.G., Kuznetsova E.P. Khirurgicheskoe lechenie dobrokachestvennykh opukholei iaichnikov. Fundamental'nye issledovaniia. 2011; 9 (1): 155–8 (in Russian).
4. Kaprin A.D., Starinsky V.V., Petrova G.V. The status of cancer care for the population of Russia in 2017. Moscow: MNIOI im. P.A. Gertsena – filial FGBU "NMITs radiologii' Minzdrava Rossii, 2018 (in Russian).
5. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359–86. DOI: 10.1002/ijc.29210
6. Zola P, Macchi C, Cibula D et al. Follow-up in Gynecological Malignancies A State of Art. Int J Gyn Cancer 2015; 25 (7): 1151–64. DOI: 10.1097/igc.0000000000000498
7. Committee Opinion No. 716. American College of Obstetricians and Gynecologists. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol 2017; 130: e146–9.
8. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am 2018; 32 (6): 943–64. DOI: 10.1016/j.hoc.2018.07.010
9. Vorob'ev A.V., Protasova A.E. Obshchie voprosy skrininga. Prakticheskaia onkologiia. 2010; 11 (2): 53–9 (in Russian).
10. Antoshechkina M.A., Savinova E.B. Icpol'zovanie biomarkerov dlia rannei diagnostiki raka iaichnikov. Kremlevskaia meditsina. Klinicheskii vestnik. 2011; 4: 91–3 (in Russian).
11. Efimova O.A. Kompleksnaia luchevaia diagnostika opukholevykh obrazovanii iaichnikov na dooperatsionnom etape. Povolzhskii onkologicheskii vestn. 2017; 3 (30): 61–4 (in Russian).
12. Silina I.A. Rak iaichnika: aspekty diagnostiki. Laboratornaia diagnostika. Vostochnaia Evropa. 2015; 3–4 (15–16): 159–68 (in Russian).
13. Batyrova L.M. Ranniaia diagnostika raka iaichnikov. Vestnik khirurgii Kazakhstana. 2011; 2: 46–7 (in Russian).
14. Mekhdiev V.E. Klinicheskoe znachenie trekhmernoi transvaginal'noi ekhografii v rezhime tsvetnogo i energeticheskogo Doplera v differentsial'noi diagnostike opukholei i opukholevidnykh obrazovanii iaichnikov. Avtoref. dis. … kand. med. nauk. M., 2011 (in Russian).
15. Ionescu CA, Matei A, Navolan D et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses. Medicine (Baltimore) 2018; 97 (31): e11762. DOI: 10.1097/MD.0000000000011762
16. Querleu D, Planchamp F, Chiva L et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 2017; 27 (7): 1534–42. DOI: 10.1097/IGC.0000000000001041
17. Gold P, Freedman S. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439–62. DOI: 10.1084/jem.121.3.439
18. Hammarstrom S, Engvall E, Sundblad G. Carcinoembryonic antigen CEA: purification, structure and antigenicproperties, in Health Control in Detection of Cancer, Skandia International Symposia. Bostrom H, Larsson T, Ljungstedt N, eds. 1976; p. 24–39.
19. Khoo S, MacKay E. Carcinoembryonic antigen (CEA) in ovarian cancer: Factors influencing its incidence and changes which occur in response to cytotoxic drugs. Br J Obstet Gynaecol 1976; 83: 753–9. DOI: 10.1111/j.1471-0528.1976.tb00739.x
20. Bast R, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig 1981; 68: 1331–7. DOI: 10.1172/JCI110380
21. Agadzhanian K.V., Ust'iantseva I.M., Petukhova O.V., Iakovleva N.V. Kliniko-metabolicheskie izmeneniia v zavisimosti ot stepeni tiazhesti endometrioza: materialy III Mezhdunarodnogo kongressa po reproduktivnoi meditsine "Problemy reproduktsii'. M., 2009; c. 163 (in Russian).
22. Li F, Tie R, Chang K et al. Meta-analysis Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer 2012; 12: 258. DOI: 10.1186/1471-2407-12-258
23. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40–6.
24. Kim YM, Whang DH, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective casecontrol study in a Korean population. Clin Chem Lab Med 2011; 49: 527–34.
25. Galgano MT, Hampton GM, Frierson HFJr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847–53.
26. Capriglione S, Luvero D, Plotti F et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol 2017; 34 (9): 164. DOI: 10.1007/s12032-017-1026-y
27. Chen F, Shen J, Wang J et al. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res 2018; 10: 1313–8. DOI: 10.2147/CMAR.S155693
28. Simmons AR, Clarke CH, Badgwell DB et al. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. Int J Gynecol Cancer 2016; 26 (6): 1070–7. DOI: 10.1097/IGC.0000000000000737
29. Ueland F, DeSimone C, Seamon L et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117: 1289–97. DOI: 10.1097/AOG.0b013e31821b5118
30. Zhang Z, Chan D. The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomark Prev 2010; 19: 2995–9. DOI: 10.1158/1055-9965.EPI-10-0580
31. Meys EM, Kaijser J, Kruitwagen RF et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 2016; 58: 17–29. DOI: 10.1016/j.ejca.2016.01.007
32. Gasparov A.S., Dubinskaia E.D., Paianidi Iu.G., Babicheva I.A. Onkoginekologicheskie aspekty kistoznykh obrazovanii iaichnikov. Vestn. RAMN. 2013; 8 (in Russian).
33. Petricoin EF, Liotta LA. SELDI TOF based serum proteomic pattern diagnostics for early detection of cancer. Cur Opinion in Biotechnology 2004; 15 (1): 24–30. DOI: 10.1016/j.copbio.2004.01.005.46
34. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003; 49 (8): 1272–5. DOI: 10.1016/j.copbio.2004.01.005
35. [Egunova M.A., Kutsenko I.G. Differentsial'naia diagnostika dobrokachestvennykh i zlokachestvennykh novoobrazovanii iaichnikov (istoriia voprosa). Zhurn. akusherstva i zhenskikh boleznei. 2016. DOI: 10.17816/JOWD65668-78 (in Russian).
36. Makarov O.V., Narimanova M.R., Moshkovskii S.A., Karpova M.A. Perspektiva novogo sposoba svoevremennoi diagnostiki raka iaichnikov na osnove ispol'zovaniia kombinatsii syvorotochnykh belkov SA125 i SAA-A1. Akusherstvo i ginekologiia. 2015; 3: 48–57 (in Russian).
37. Gerfanova E.V., Ashrafian L.A., Antonova I.B. et al. Skrining raka iaichnikov: real'nost' i perspektivy. Obzor literatury. Opukholi zhenskoi reproduktivnoi sistemy. 2015; 11 (1): 69–75 (in Russian).
38. Suh-Burgmann E, Flanagan T, Osinski T et al. Prospective Validation of a Standardized Ultrasonography-Based Ovarian Cancer Risk Assessment System. Obstet Gynecol 2018; 132 (5): 1101–11. DOI: 10.1097/AOG.0000000000002939
39. Valentin L, Ameye L, Savelli L et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol 2011; 38 (4): 456–65. DOI: 10.1002/uog.9030
40. Sehgal N. Efficacy of Color Doppler Ultrasonography in Differentiation of Ovarian Masses. J Midlife Health 2019; 10 (1): 22–8. DOI: 10.4103/jmh.JMH_23_18
41. Kaijser J, Bourne T, Valentin L et al. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol 2013; 41 (1): 9–20. DOI: 10.1002/uog.12323
42. Garg S, Kaur A, Mohi JK et al. Evaluation of IOTA Simple Ultrasound Rules to Distinguish Benign and Malignant Ovarian Tumours. J Clin Diagn Res 2017; 11 (8): TC06–TC09. DOI: 10.7860/JCDR/2017/26790.10353
43. Moro F, Pasciuto T, Djokovic D et al. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol 2019; 53 (1): 116–23. DOI: 10.1002/uog.19174
44. Wynants L, Timmerman D, Verbakel JY et al. Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis. Clin Cancer Res 2017; 23 (17): 5082–90. DOI: 10.1158/1078-0432.CCR-16-3248
45. Podzolkova N.M., L'vova A.G., Zubarev A.R., Osadchev V.B. Differentsial'naia diagnostika opukholei i opukholevidnykh obrazovanii iaichnikov: klinicheskoe znachenie trekhmernoi ekhografii. Voprosy ginekologii, akusherstva i perinatologii. 2009; 8 (1): 7–16 (in Russian).
46. Bratchikova O.V. Novye tekhnologii (3D/4D-UZI) v opredelenii kharaktera iaichnikovykh obrazovanii. Avtoref. dis. … kand. med. nauk. M., 2011 (in Russian).
47. Ashrafian L.A., Ivashina S.V., Kogai N.V. et al. Vozmozhnosti sonoelastometrii dlia differentsial'noi diagnostiki dobrokachestvennykh i zlokachestvennykh opukholei iaichnikov. Opukholi zhenskoi reproduktivnoi sistemy. 2012; 2. (in Russian).
48. Henri M, Florence E, Aurore B et al. Contribution of contrast-enhanced ultrasound with Sonovue to describe the microvascularization of uterine fibroid tumors before and after uterine artery embolization. Eur J Obstet Gynecol Reprod Biol 2014; 181: 104–10. DOI: 10.1016/j.ejogrb.2014.07.030
49. Ma X, Zhao Y, Zhang B et al. Contrast-enhanced ultrasound for differential diagnosis of malignant and benign ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 46 (3): 277–83. DOI: 10.1002/uog.14800
50. Meng W, Ying W, Qichao Z et al. Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer. Saudi Med J 2017; 38 (6): 592–7. DOI: 10.15537/smj.2017.6.19790
51. Liu Z, Yang F, Zhang Y et al. Conventional, Doppler and Contrast-Enhanced Ultrasonography in Differential Diagnosis of Ovarian Masses. Cell Physiol Biochem 2016; 39 (6): 2398–408.
52. Ageev A.S., Chekalova M.A., Patiutko Iu.I. Ul'trazvukovoe issledovanie s kontrastnym usileniem v diagnostike metastaticheskogo porazheniia pecheni. Ul'trazvukovaia i funktsional'naia diagnostika. 2016; 2: 9–16 (in Russian).
53. Ma X, Zhao Y, Zhang B et al. Contrast-enhanced ultrasound for differential diagnosis of benign and malignant ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 46 (3). DOI: 10.1002/uog.14800
54. Sonov'iu. Nauchnaia monografiia. Dinamicheskoe kontrastnoe usilenie v rezhime real'nogo vremeni. 2013. http://cp6.megagroup.ru/
d/178726/d/monografiya-sonovyu-2013.pdf (in Russian).
55. Davydov A.I., Kuz'mina T.E. Kontrastno-usilennye ul'trazvukovye issledovaniia v ginekologii. Voprosy ginekologii, akusherstva i perinatologii. 2017; 16 (6): 50–8.
DOI: 10.20953/1726-1678-2017-6-50-58 (in Russian).
56. Sahdev A. CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvis disease for surgical planning. Cancer Imaging 2016.
57. Pietro VF, Giancarlo AS et al. MRI of ovarian masses: classification and differential diagnosis insights imaging. Insights Imaging 2016;
7 (1): 21–41.
58. Forstner R, Thamassin-Naggara I et al. ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update. Eur Radiol 2017; 27 (6): 2248–57.
59. Palmeiro MM et al. MRI classification of the Sonographically Indeterminated Adnexal Lesions. Acta Radiologica Portuguesa 2016; XXVIII (108): 37–47.
60. Ma FH, Qiang JW, Cai SQ et al. MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors. AJR Am J Roentgenol 2015; 204 (6): W724–30. DOI: 10.2214/AJR.14.13391
61. Solopova A.E., Ternovoi S.K., Ustiuzhanin D.V., Makatsariia A.D. Magnitno-rezonansnaia spektroskopiia v differentsial'noi diagnostike opukholei iaichnika. Metodika, diagnosticheskie vozmozhnosti, ogranicheniia. DOI: 10.21569/2222-7415-2017-7-1-84-93 (in Russian).
62. Sidhu S, Falzon G, Hart SA et al. Classification of breast tissue using a laboratory system for small-angle x-ray scattering (SAXS). Phys Med Biol 2011; 56: 6779–91. DOI: 10.1088/0031-9155/56/21/002
63. Jensen TH, Bech M, Bunk O et al. Brain tumor imaging using small-angle Х-ray scattering tomography. Phys Med Biol 2011; 56: 1717–26. DOI: 10.1088/0031-9155/56/6/012
2. Борисова Е.А. Комплексная дифференциальная диагностика опухолей придатков матки. Автореф. дис. … канд. мед. наук. Иркутск, 2018.
[Borisova E.A. Kompleksnaia differentsial'naia diagnostika opukholei pridatkov matki. Avtoref. dis. … kand. med. nauk. Irkutsk, 2018 (in Russian).]
3. Серебренникова К.Г., Кузнецова Е.П. Хирургическое лечение доброкачественных опухолей яичников. Фундаментальные исследования. 2011; 9 (1): 155–8.
[Serebrennikova K.G., Kuznetsova E.P. Khirurgicheskoe lechenie dobrokachestvennykh opukholei iaichnikov. Fundamental'nye issledovaniia. 2011; 9 (1): 155–8 (in Russian).]
4. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
[Kaprin A.D., Starinsky V.V., Petrova G.V. The status of cancer care for the population of Russia in 2017. Moscow: MNIOI im. P.A. Gertsena – filial FGBU "NMITs radiologii' Minzdrava Rossii, 2018 (in Russian).]
5. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359–86. DOI: 10.1002/ijc.29210
6. Zola P, Macchi C, Cibula D et al. Follow-up in Gynecological Malignancies A State of Art. Int J Gyn Cancer 2015; 25 (7): 1151–64. DOI: 10.1097/igc.0000000000000498
7. Committee Opinion No. 716. American College of Obstetricians and Gynecologists. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol 2017; 130: e146–9.
8. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am 2018; 32 (6): 943–64. DOI: 10.1016/j.hoc.2018.07.010
9. Воробьев А.В., Протасова А.Э. Общие вопросы скрининга. Практическая онкология. 2010; 11 (2): 53–9.
[Vorob'ev A.V., Protasova A.E. Obshchie voprosy skrininga. Prakticheskaia onkologiia. 2010; 11 (2): 53–9 (in Russian).]
10. Антошечкина М.А., Савинова Е.Б. Иcпользование биомаркеров для ранней диагностики рака яичников. Кремлевская медицина. Клинический вестник. 2011; 4: 91–3.
[Antoshechkina M.A., Savinova E.B. Icpol'zovanie biomarkerov dlia rannei diagnostiki raka iaichnikov. Kremlevskaia meditsina. Klinicheskii vestnik. 2011; 4: 91–3 (in Russian).]
11. Ефимова О.А. Комплексная лучевая диагностика опухолевых образований яичников на дооперационном этапе. Поволжский онкологический вестн. 2017; 3 (30): 61–4.
[Efimova O.A. Kompleksnaia luchevaia diagnostika opukholevykh obrazovanii iaichnikov na dooperatsionnom etape. Povolzhskii onkologicheskii vestn. 2017; 3 (30): 61–4 (in Russian).]
12. Силина И.А. Рак яичника: аспекты диагностики. Лабораторная диагностика. Восточная Европа. 2015; 3–4 (15–16): 159–68.
[Silina I.A. Rak iaichnika: aspekty diagnostiki. Laboratornaia diagnostika. Vostochnaia Evropa. 2015; 3–4 (15–16): 159–68 (in Russian).]
13. Батырова Л.М. Ранняя диагностика рака яичников. Вестник хирургии Казахстана. 2011; 2: 46–7.
[Batyrova L.M. Ranniaia diagnostika raka iaichnikov. Vestnik khirurgii Kazakhstana. 2011; 2: 46–7 (in Russian).]
14. Мехдиев В.Э. Клиническое значение трехмерной трансвагинальной эхографии в режиме цветного и энергетического Доплера в дифференциальной диагностике опухолей и опухолевидных образований яичников. Автореф. дис. … канд. мед. наук. М., 2011.
[Mekhdiev V.E. Klinicheskoe znachenie trekhmernoi transvaginal'noi ekhografii v rezhime tsvetnogo i energeticheskogo Doplera v differentsial'noi diagnostike opukholei i opukholevidnykh obrazovanii iaichnikov. Avtoref. dis. … kand. med. nauk. M., 2011 (in Russian).]
15. Ionescu CA, Matei A, Navolan D et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses. Medicine (Baltimore) 2018; 97 (31): e11762. DOI: 10.1097/MD.0000000000011762
16. Querleu D, Planchamp F, Chiva L et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 2017; 27 (7): 1534–42. DOI: 10.1097/IGC.0000000000001041
17. Gold P, Freedman S. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439–62. DOI: 10.1084/jem.121.3.439
18. Hammarstrom S, Engvall E, Sundblad G. Carcinoembryonic antigen CEA: purification, structure and antigenicproperties, in Health Control in Detection of Cancer, Skandia International Symposia. Bostrom H, Larsson T, Ljungstedt N, eds. 1976; p. 24–39.
19. Khoo S, MacKay E. Carcinoembryonic antigen (CEA) in ovarian cancer: Factors influencing its incidence and changes which occur in response to cytotoxic drugs. Br J Obstet Gynaecol 1976; 83: 753–9. DOI: 10.1111/j.1471-0528.1976.tb00739.x
20. Bast R, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig 1981; 68: 1331–7. DOI: 10.1172/JCI110380
21. Агаджанян К.В., Устьянцева И.М., Петухова О.В., Яковлева Н.В. Клинико-метаболические изменения в зависимости от степени тяжести эндометриоза: материалы III Международного конгресса по репродуктивной медицине «Проблемы репродукции». М., 2009; c. 163.
[Agadzhanian K.V., Ust'iantseva I.M., Petukhova O.V., Iakovleva N.V. Kliniko-metabolicheskie izmeneniia v zavisimosti ot stepeni tiazhesti endometrioza: materialy III Mezhdunarodnogo kongressa po reproduktivnoi meditsine "Problemy reproduktsii'. M., 2009; c. 163 (in Russian).]
22. Li F, Tie R, Chang K et al. Meta-analysis Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer 2012; 12: 258. DOI: 10.1186/1471-2407-12-258
23. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40–6.
24. Kim YM, Whang DH, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective casecontrol study in a Korean population. Clin Chem Lab Med 2011; 49: 527–34.
25. Galgano MT, Hampton GM, Frierson HFJr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847–53.
26. Capriglione S, Luvero D, Plotti F et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol 2017; 34 (9): 164. DOI: 10.1007/s12032-017-1026-y
27. Chen F, Shen J, Wang J et al. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res 2018; 10: 1313–8. DOI: 10.2147/CMAR.S155693
28. Simmons AR, Clarke CH, Badgwell DB et al. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. Int J Gynecol Cancer 2016; 26 (6): 1070–7. DOI: 10.1097/IGC.0000000000000737
29. Ueland F, DeSimone C, Seamon L et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117: 1289–97. DOI: 10.1097/AOG.0b013e31821b5118
30. Zhang Z, Chan D. The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomark Prev 2010; 19: 2995–9. DOI: 10.1158/1055-9965.EPI-10-0580
31. Meys EM, Kaijser J, Kruitwagen RF et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 2016; 58: 17–29. DOI: 10.1016/j.ejca.2016.01.007
32. Гаспаров А.С., Дубинская Е.Д., Паяниди Ю.Г., Бабичева И.А. Онкогинекологические аспекты кистозных образований яичников. Вестн. РАМН. 2013; 8.
[Gasparov A.S., Dubinskaia E.D., Paianidi Iu.G., Babicheva I.A. Onkoginekologicheskie aspekty kistoznykh obrazovanii iaichnikov. Vestn. RAMN. 2013; 8 (in Russian).]
33. Petricoin EF, Liotta LA. SELDI TOF based serum proteomic pattern diagnostics for early detection of cancer. Cur Opinion in Biotechnology 2004; 15 (1): 24–30. DOI: 10.1016/j.copbio.2004.01.005.46
34. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003; 49 (8): 1272–5. DOI: 10.1016/j.copbio.2004.01.005
35. Егунова М.А., Куценко И.Г. Дифференциальная диагностика доброкачественных и злокачественных новообразований яичников (история вопроса). Журн. акушерства и женских болезней. 2016. DOI: 10.17816/JOWD65668-78
[Egunova M.A., Kutsenko I.G. Differentsial'naia diagnostika dobrokachestvennykh i zlokachestvennykh novoobrazovanii iaichnikov (istoriia voprosa). Zhurn. akusherstva i zhenskikh boleznei. 2016. DOI: 10.17816/JOWD65668-78 (in Russian).]
36. Макаров О.В., Нариманова М.Р., Мошковский С.А., Карпова М.А. Перспектива нового способа своевременной диагностики рака яичников на основе использования комбинации сывороточных белков СА125 и SAA-A1. Акушерство и гинекология. 2015; 3: 48–57.
[Makarov O.V., Narimanova M.R., Moshkovskii S.A., Karpova M.A. Perspektiva novogo sposoba svoevremennoi diagnostiki raka iaichnikov na osnove ispol'zovaniia kombinatsii syvorotochnykh belkov SA125 i SAA-A1. Akusherstvo i ginekologiia. 2015; 3: 48–57 (in Russian).]
37. Герфанова Е.В., Ашрафян Л.А., Антонова И.Б. и др. Скрининг рака яичников: реальность и перспективы. Обзор литературы. Опухоли женской репродуктивной системы. 2015; 11 (1): 69–75.
[Gerfanova E.V., Ashrafian L.A., Antonova I.B. et al. Skrining raka iaichnikov: real'nost' i perspektivy. Obzor literatury. Opukholi zhenskoi reproduktivnoi sistemy. 2015; 11 (1): 69–75 (in Russian).]
38. Suh-Burgmann E, Flanagan T, Osinski T et al. Prospective Validation of a Standardized Ultrasonography-Based Ovarian Cancer Risk Assessment System. Obstet Gynecol 2018; 132 (5): 1101–11. DOI: 10.1097/AOG.0000000000002939
39. Valentin L, Ameye L, Savelli L et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol 2011; 38 (4): 456–65. DOI: 10.1002/uog.9030
40. Sehgal N. Efficacy of Color Doppler Ultrasonography in Differentiation of Ovarian Masses. J Midlife Health 2019; 10 (1): 22–8. DOI: 10.4103/jmh.JMH_23_18
41. Kaijser J, Bourne T, Valentin L et al. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol 2013; 41 (1): 9–20. DOI: 10.1002/uog.12323
42. Garg S, Kaur A, Mohi JK et al. Evaluation of IOTA Simple Ultrasound Rules to Distinguish Benign and Malignant Ovarian Tumours. J Clin Diagn Res 2017; 11 (8): TC06–TC09. DOI: 10.7860/JCDR/2017/26790.10353
43. Moro F, Pasciuto T, Djokovic D et al. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol 2019; 53 (1): 116–23. DOI: 10.1002/uog.19174
44. Wynants L, Timmerman D, Verbakel JY et al. Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis. Clin Cancer Res 2017; 23 (17): 5082–90. DOI: 10.1158/1078-0432.CCR-16-3248
45. Подзолкова Н.М., Львова А.Г., Зубарев А.Р., Осадчев В.Б. Дифференциальная диагностика опухолей и опухолевидных образований яичников: клиническое значение трехмерной эхографии. Вопросы гинекологии, акушерства и перинатологии. 2009; 8 (1): 7–16.
[Podzolkova N.M., L'vova A.G., Zubarev A.R., Osadchev V.B. Differentsial'naia diagnostika opukholei i opukholevidnykh obrazovanii iaichnikov: klinicheskoe znachenie trekhmernoi ekhografii. Voprosy ginekologii, akusherstva i perinatologii. 2009; 8 (1): 7–16 (in Russian).]
46. Братчикова О.В. Новые технологии (3D/4D-УЗИ) в определении характера яичниковых образований. Автореф. дис. … канд. мед. наук. М., 2011.
[Bratchikova O.V. Novye tekhnologii (3D/4D-UZI) v opredelenii kharaktera iaichnikovykh obrazovanii. Avtoref. dis. … kand. med. nauk. M., 2011 (in Russian).]
47. Ашрафян Л.А., Ивашина С.В., Когай Н.В. и др. Возможности соноэластометрии для дифференциальной диагностики доброкачественных и злокачественных опухолей яичников. Опухоли женской репродуктивной системы. 2012; 2.
[Ashrafian L.A., Ivashina S.V., Kogai N.V. et al. Vozmozhnosti sonoelastometrii dlia differentsial'noi diagnostiki dobrokachestvennykh i zlokachestvennykh opukholei iaichnikov. Opukholi zhenskoi reproduktivnoi sistemy. 2012; 2. (in Russian).]
48. Henri M, Florence E, Aurore B et al. Contribution of contrast-enhanced ultrasound with Sonovue to describe the microvascularization of uterine fibroid tumors before and after uterine artery embolization. Eur J Obstet Gynecol Reprod Biol 2014; 181: 104–10. DOI: 10.1016/j.ejogrb.2014.07.030
49. Ma X, Zhao Y, Zhang B et al. Contrast-enhanced ultrasound for differential diagnosis of malignant and benign ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 46 (3): 277–83. DOI: 10.1002/uog.14800
50. Meng W, Ying W, Qichao Z et al. Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer. Saudi Med J 2017; 38 (6): 592–7. DOI: 10.15537/smj.2017.6.19790
51. Liu Z, Yang F, Zhang Y et al. Conventional, Doppler and Contrast-Enhanced Ultrasonography in Differential Diagnosis of Ovarian Masses. Cell Physiol Biochem 2016; 39 (6): 2398–408.
52. Агеев А.С., Чекалова М.А., Патютко Ю.И. Ультразвуковое исследование с контрастным усилением в диагностике метастатического поражения печени. Ультразвуковая и функциональная диагностика. 2016; 2: 9–16.
[Ageev A.S., Chekalova M.A., Patiutko Iu.I. Ul'trazvukovoe issledovanie s kontrastnym usileniem v diagnostike metastaticheskogo porazheniia pecheni. Ul'trazvukovaia i funktsional'naia diagnostika. 2016; 2: 9–16 (in Russian).]
53. Ma X, Zhao Y, Zhang B et al. Contrast-enhanced ultrasound for differential diagnosis of benign and malignant ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 46 (3). DOI: 10.1002/uog.14800
54. Соновью. Научная монография. Динамическое контрастное усиление в режиме реального времени. 2013. http://cp6.megagroup.ru/
d/178726/d/monografiya-sonovyu-2013.pdf
[Sonov'iu. Nauchnaia monografiia. Dinamicheskoe kontrastnoe usilenie v rezhime real'nogo vremeni. 2013. http://cp6.megagroup.ru/
d/178726/d/monografiya-sonovyu-2013.pdf (in Russian).]
55. Давыдов А.И., Кузьмина Т.Е. Контрастно-усиленные ультразвуковые исследования в гинекологии. Вопросы гинекологии, акушерства и перинатологии. 2017; 16 (6): 50–8. DOI: 10.20953/1726-1678-2017-6-50-58
[Davydov A.I., Kuz'mina T.E. Kontrastno-usilennye ul'trazvukovye issledovaniia v ginekologii. Voprosy ginekologii, akusherstva i perinatologii. 2017; 16 (6): 50–8.
DOI: 10.20953/1726-1678-2017-6-50-58 (in Russian).]
56. Sahdev A. CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvis disease for surgical planning. Cancer Imaging 2016.
57. Pietro VF, Giancarlo AS et al. MRI of ovarian masses: classification and differential diagnosis insights imaging. Insights Imaging 2016;
7 (1): 21–41.
58. Forstner R, Thamassin-Naggara I et al. ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update. Eur Radiol 2017; 27 (6): 2248–57.
59. Palmeiro MM et al. MRI classification of the Sonographically Indeterminated Adnexal Lesions. Acta Radiologica Portuguesa 2016; XXVIII (108): 37–47.
60. Ma FH, Qiang JW, Cai SQ et al. MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors. AJR Am J Roentgenol 2015; 204 (6): W724–30. DOI: 10.2214/AJR.14.13391
61. Солопова А.Е., Терновой С.К., Устюжанин Д.В., Макаца-
рия А.Д. Магнитно-резонансная спектроскопия в дифференциальной диагностике опухолей яичника. Методика, диагностические возможности, ограничения. DOI: 10.21569/2222-7415-2017-7-1-84-93
[Solopova A.E., Ternovoi S.K., Ustiuzhanin D.V., Makatsariia A.D. Magnitno-rezonansnaia spektroskopiia v differentsial'noi diagnostike opukholei iaichnika. Metodika, diagnosticheskie vozmozhnosti, ogranicheniia. DOI: 10.21569/2222-7415-2017-7-1-84-93 (in Russian).]
62. Sidhu S, Falzon G, Hart SA et al. Classification of breast tissue using a laboratory system for small-angle x-ray scattering (SAXS). Phys Med Biol 2011; 56: 6779–91. DOI: 10.1088/0031-9155/56/21/002
63. Jensen TH, Bech M, Bunk O et al. Brain tumor imaging using small-angle Х-ray scattering tomography. Phys Med Biol 2011; 56: 1717–26. DOI: 10.1088/0031-9155/56/6/012
________________________________________________
2. Borisova E.A. Kompleksnaia differentsial'naia diagnostika opukholei pridatkov matki. Avtoref. dis. … kand. med. nauk. Irkutsk, 2018 (in Russian).
3. Serebrennikova K.G., Kuznetsova E.P. Khirurgicheskoe lechenie dobrokachestvennykh opukholei iaichnikov. Fundamental'nye issledovaniia. 2011; 9 (1): 155–8 (in Russian).
4. Kaprin A.D., Starinsky V.V., Petrova G.V. The status of cancer care for the population of Russia in 2017. Moscow: MNIOI im. P.A. Gertsena – filial FGBU "NMITs radiologii' Minzdrava Rossii, 2018 (in Russian).
5. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359–86. DOI: 10.1002/ijc.29210
6. Zola P, Macchi C, Cibula D et al. Follow-up in Gynecological Malignancies A State of Art. Int J Gyn Cancer 2015; 25 (7): 1151–64. DOI: 10.1097/igc.0000000000000498
7. Committee Opinion No. 716. American College of Obstetricians and Gynecologists. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol 2017; 130: e146–9.
8. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am 2018; 32 (6): 943–64. DOI: 10.1016/j.hoc.2018.07.010
9. Vorob'ev A.V., Protasova A.E. Obshchie voprosy skrininga. Prakticheskaia onkologiia. 2010; 11 (2): 53–9 (in Russian).
10. Antoshechkina M.A., Savinova E.B. Icpol'zovanie biomarkerov dlia rannei diagnostiki raka iaichnikov. Kremlevskaia meditsina. Klinicheskii vestnik. 2011; 4: 91–3 (in Russian).
11. Efimova O.A. Kompleksnaia luchevaia diagnostika opukholevykh obrazovanii iaichnikov na dooperatsionnom etape. Povolzhskii onkologicheskii vestn. 2017; 3 (30): 61–4 (in Russian).
12. Silina I.A. Rak iaichnika: aspekty diagnostiki. Laboratornaia diagnostika. Vostochnaia Evropa. 2015; 3–4 (15–16): 159–68 (in Russian).
13. Batyrova L.M. Ranniaia diagnostika raka iaichnikov. Vestnik khirurgii Kazakhstana. 2011; 2: 46–7 (in Russian).
14. Mekhdiev V.E. Klinicheskoe znachenie trekhmernoi transvaginal'noi ekhografii v rezhime tsvetnogo i energeticheskogo Doplera v differentsial'noi diagnostike opukholei i opukholevidnykh obrazovanii iaichnikov. Avtoref. dis. … kand. med. nauk. M., 2011 (in Russian).
15. Ionescu CA, Matei A, Navolan D et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses. Medicine (Baltimore) 2018; 97 (31): e11762. DOI: 10.1097/MD.0000000000011762
16. Querleu D, Planchamp F, Chiva L et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer 2017; 27 (7): 1534–42. DOI: 10.1097/IGC.0000000000001041
17. Gold P, Freedman S. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439–62. DOI: 10.1084/jem.121.3.439
18. Hammarstrom S, Engvall E, Sundblad G. Carcinoembryonic antigen CEA: purification, structure and antigenicproperties, in Health Control in Detection of Cancer, Skandia International Symposia. Bostrom H, Larsson T, Ljungstedt N, eds. 1976; p. 24–39.
19. Khoo S, MacKay E. Carcinoembryonic antigen (CEA) in ovarian cancer: Factors influencing its incidence and changes which occur in response to cytotoxic drugs. Br J Obstet Gynaecol 1976; 83: 753–9. DOI: 10.1111/j.1471-0528.1976.tb00739.x
20. Bast R, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig 1981; 68: 1331–7. DOI: 10.1172/JCI110380
21. Agadzhanian K.V., Ust'iantseva I.M., Petukhova O.V., Iakovleva N.V. Kliniko-metabolicheskie izmeneniia v zavisimosti ot stepeni tiazhesti endometrioza: materialy III Mezhdunarodnogo kongressa po reproduktivnoi meditsine "Problemy reproduktsii'. M., 2009; c. 163 (in Russian).
22. Li F, Tie R, Chang K et al. Meta-analysis Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer 2012; 12: 258. DOI: 10.1186/1471-2407-12-258
23. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112: 40–6.
24. Kim YM, Whang DH, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective casecontrol study in a Korean population. Clin Chem Lab Med 2011; 49: 527–34.
25. Galgano MT, Hampton GM, Frierson HFJr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847–53.
26. Capriglione S, Luvero D, Plotti F et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol 2017; 34 (9): 164. DOI: 10.1007/s12032-017-1026-y
27. Chen F, Shen J, Wang J et al. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res 2018; 10: 1313–8. DOI: 10.2147/CMAR.S155693
28. Simmons AR, Clarke CH, Badgwell DB et al. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. Int J Gynecol Cancer 2016; 26 (6): 1070–7. DOI: 10.1097/IGC.0000000000000737
29. Ueland F, DeSimone C, Seamon L et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117: 1289–97. DOI: 10.1097/AOG.0b013e31821b5118
30. Zhang Z, Chan D. The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomark Prev 2010; 19: 2995–9. DOI: 10.1158/1055-9965.EPI-10-0580
31. Meys EM, Kaijser J, Kruitwagen RF et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 2016; 58: 17–29. DOI: 10.1016/j.ejca.2016.01.007
32. Gasparov A.S., Dubinskaia E.D., Paianidi Iu.G., Babicheva I.A. Onkoginekologicheskie aspekty kistoznykh obrazovanii iaichnikov. Vestn. RAMN. 2013; 8 (in Russian).
33. Petricoin EF, Liotta LA. SELDI TOF based serum proteomic pattern diagnostics for early detection of cancer. Cur Opinion in Biotechnology 2004; 15 (1): 24–30. DOI: 10.1016/j.copbio.2004.01.005.46
34. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003; 49 (8): 1272–5. DOI: 10.1016/j.copbio.2004.01.005
35. [Egunova M.A., Kutsenko I.G. Differentsial'naia diagnostika dobrokachestvennykh i zlokachestvennykh novoobrazovanii iaichnikov (istoriia voprosa). Zhurn. akusherstva i zhenskikh boleznei. 2016. DOI: 10.17816/JOWD65668-78 (in Russian).
36. Makarov O.V., Narimanova M.R., Moshkovskii S.A., Karpova M.A. Perspektiva novogo sposoba svoevremennoi diagnostiki raka iaichnikov na osnove ispol'zovaniia kombinatsii syvorotochnykh belkov SA125 i SAA-A1. Akusherstvo i ginekologiia. 2015; 3: 48–57 (in Russian).
37. Gerfanova E.V., Ashrafian L.A., Antonova I.B. et al. Skrining raka iaichnikov: real'nost' i perspektivy. Obzor literatury. Opukholi zhenskoi reproduktivnoi sistemy. 2015; 11 (1): 69–75 (in Russian).
38. Suh-Burgmann E, Flanagan T, Osinski T et al. Prospective Validation of a Standardized Ultrasonography-Based Ovarian Cancer Risk Assessment System. Obstet Gynecol 2018; 132 (5): 1101–11. DOI: 10.1097/AOG.0000000000002939
39. Valentin L, Ameye L, Savelli L et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol 2011; 38 (4): 456–65. DOI: 10.1002/uog.9030
40. Sehgal N. Efficacy of Color Doppler Ultrasonography in Differentiation of Ovarian Masses. J Midlife Health 2019; 10 (1): 22–8. DOI: 10.4103/jmh.JMH_23_18
41. Kaijser J, Bourne T, Valentin L et al. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol 2013; 41 (1): 9–20. DOI: 10.1002/uog.12323
42. Garg S, Kaur A, Mohi JK et al. Evaluation of IOTA Simple Ultrasound Rules to Distinguish Benign and Malignant Ovarian Tumours. J Clin Diagn Res 2017; 11 (8): TC06–TC09. DOI: 10.7860/JCDR/2017/26790.10353
43. Moro F, Pasciuto T, Djokovic D et al. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol 2019; 53 (1): 116–23. DOI: 10.1002/uog.19174
44. Wynants L, Timmerman D, Verbakel JY et al. Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis. Clin Cancer Res 2017; 23 (17): 5082–90. DOI: 10.1158/1078-0432.CCR-16-3248
45. Podzolkova N.M., L'vova A.G., Zubarev A.R., Osadchev V.B. Differentsial'naia diagnostika opukholei i opukholevidnykh obrazovanii iaichnikov: klinicheskoe znachenie trekhmernoi ekhografii. Voprosy ginekologii, akusherstva i perinatologii. 2009; 8 (1): 7–16 (in Russian).
46. Bratchikova O.V. Novye tekhnologii (3D/4D-UZI) v opredelenii kharaktera iaichnikovykh obrazovanii. Avtoref. dis. … kand. med. nauk. M., 2011 (in Russian).
47. Ashrafian L.A., Ivashina S.V., Kogai N.V. et al. Vozmozhnosti sonoelastometrii dlia differentsial'noi diagnostiki dobrokachestvennykh i zlokachestvennykh opukholei iaichnikov. Opukholi zhenskoi reproduktivnoi sistemy. 2012; 2. (in Russian).
48. Henri M, Florence E, Aurore B et al. Contribution of contrast-enhanced ultrasound with Sonovue to describe the microvascularization of uterine fibroid tumors before and after uterine artery embolization. Eur J Obstet Gynecol Reprod Biol 2014; 181: 104–10. DOI: 10.1016/j.ejogrb.2014.07.030
49. Ma X, Zhao Y, Zhang B et al. Contrast-enhanced ultrasound for differential diagnosis of malignant and benign ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 46 (3): 277–83. DOI: 10.1002/uog.14800
50. Meng W, Ying W, Qichao Z et al. Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer. Saudi Med J 2017; 38 (6): 592–7. DOI: 10.15537/smj.2017.6.19790
51. Liu Z, Yang F, Zhang Y et al. Conventional, Doppler and Contrast-Enhanced Ultrasonography in Differential Diagnosis of Ovarian Masses. Cell Physiol Biochem 2016; 39 (6): 2398–408.
52. Ageev A.S., Chekalova M.A., Patiutko Iu.I. Ul'trazvukovoe issledovanie s kontrastnym usileniem v diagnostike metastaticheskogo porazheniia pecheni. Ul'trazvukovaia i funktsional'naia diagnostika. 2016; 2: 9–16 (in Russian).
53. Ma X, Zhao Y, Zhang B et al. Contrast-enhanced ultrasound for differential diagnosis of benign and malignant ovarian tumors: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 46 (3). DOI: 10.1002/uog.14800
54. Sonov'iu. Nauchnaia monografiia. Dinamicheskoe kontrastnoe usilenie v rezhime real'nogo vremeni. 2013. http://cp6.megagroup.ru/
d/178726/d/monografiya-sonovyu-2013.pdf (in Russian).
55. Davydov A.I., Kuz'mina T.E. Kontrastno-usilennye ul'trazvukovye issledovaniia v ginekologii. Voprosy ginekologii, akusherstva i perinatologii. 2017; 16 (6): 50–8.
DOI: 10.20953/1726-1678-2017-6-50-58 (in Russian).
56. Sahdev A. CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvis disease for surgical planning. Cancer Imaging 2016.
57. Pietro VF, Giancarlo AS et al. MRI of ovarian masses: classification and differential diagnosis insights imaging. Insights Imaging 2016;
7 (1): 21–41.
58. Forstner R, Thamassin-Naggara I et al. ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update. Eur Radiol 2017; 27 (6): 2248–57.
59. Palmeiro MM et al. MRI classification of the Sonographically Indeterminated Adnexal Lesions. Acta Radiologica Portuguesa 2016; XXVIII (108): 37–47.
60. Ma FH, Qiang JW, Cai SQ et al. MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors. AJR Am J Roentgenol 2015; 204 (6): W724–30. DOI: 10.2214/AJR.14.13391
61. Solopova A.E., Ternovoi S.K., Ustiuzhanin D.V., Makatsariia A.D. Magnitno-rezonansnaia spektroskopiia v differentsial'noi diagnostike opukholei iaichnika. Metodika, diagnosticheskie vozmozhnosti, ogranicheniia. DOI: 10.21569/2222-7415-2017-7-1-84-93 (in Russian).
62. Sidhu S, Falzon G, Hart SA et al. Classification of breast tissue using a laboratory system for small-angle x-ray scattering (SAXS). Phys Med Biol 2011; 56: 6779–91. DOI: 10.1088/0031-9155/56/21/002
63. Jensen TH, Bech M, Bunk O et al. Brain tumor imaging using small-angle Х-ray scattering tomography. Phys Med Biol 2011; 56: 1717–26. DOI: 10.1088/0031-9155/56/6/012
Авторы
Н.М. Подзолкова*, В.Б. Осадчев, К.В. Бабков, Н.Е. Сафонова
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*podzolkova@gmail.com
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*podzolkova@gmail.com
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*podzolkova@gmail.com
________________________________________________
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*podzolkova@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.